Health monitoring company BioIntelliSense has acquired AlertWatch, a US Food and Drug Administration (FDA)-cleared, clinically proven patient monitoring solution, to expand its monitoring solutions portfolio.
The financial terms of the deal were not disclosed.
Based in Ann Arbor, Michigan, AlertWatch creates and markets clinical decision support systems for hospitals. The firm has received four FDA 510(k) clearances for its specialised product offerings for the operating room, intensive care unit, and labour and delivery unit.
AlertWatch offers integration, data analysis as well as a patented intuitive display of contextual patient data to facilitate clinical decisions that are more efficient and actionable.
BioIntelliSense founder and CEO James Mault said: “The addition of AlertWatch offers healthcare providers comprehensive continuous monitoring solutions, and an accelerated path from adoption to full scale utilization.
“The patented AlertWatch multi-parameter interface displays and analyzes data from inpatient vitals, the electronic medical record (EMR), laboratory systems and BioIntelliSense medical-grade wearables, to provide clinical intelligence across care settings and acuity levels.”
BioIntellisense developed BioButton, a wearable device for remote patient monitoring and early detection.
The AlertWatch clinical intelligence and triage system is said to integrate seamlessly with the BioButton wearables to provide scalable in-hospital patient monitoring and at-home remote care.
The centralised triage dashboard of AlertWatch is said to aggregate data and gives clinicians a composite view of the vital sign trends of patients. It also simultaneously carries out advanced analytics and alerting to help with proactive clinical decisions.
The BioIntelliSense and AlertWatch platforms are said to be interoperable solutions and offer third-party and EMR system integration and data-sharing capabilities.
AlertWatch founder and president Kevin Tremper said: “By joining forces with BioIntelliSense, we are thrilled to greatly expand the reach and adoption of our world-class clinical decision support solution.
“The workflow automation benefits not only help to reduce hospital stays and costs, but also assist clinicians and nurses by alerting them with highly actionable information that prioritises and personalises patient care.”
BioIntelliSense said that as part of a recently announced partnership with Medtronic, the latter’s patient monitoring business will handle the distribution of AlertWatch in hospitals across the US as a new offering in its HealthCast intelligent patient manager portfolio.
